HCQ: The drug that won’t die…

New peer-reviewed study finds hydroxychloroquine’s life-saving benefits.


The results of a large-scale analysis, conducted by the prestigious Henry Ford Health System, was published last week in the peer-reviewed International Journal of Infectious Diseases.

The study examined 2,541 patients who had been hospitalized in six Henry Ford hospitals between March 10 and May 2, 2020.

More than 90% of the patients receiving hydroxychloroquine were treated with the drug within 48 hours of admission to the hospital.

The study’s fundamental finding:

26.4% of patients who did not receive hydroxychloroquine died.

But among those who received hydroxychloroquine, fewer than half that number — 13% — died.

The difference in mortality is, by all measures, statistically significant.

How can that be?


According to the authors:

We attribute our findings that differ from other studies to early treatment, and part of a combination of interventions that were done in supportive care of patients, including careful cardiac monitoring.

Patients who were monitored for a heart condition were recommended not to take the treatment.

None of the (hydroxychloroquine) patients experienced side effects.

The findings have been highly analyzed and peer-reviewed.

The Henry Ford dosing was differed from other studies not showing a benefit of the drug.

And other studies are either not peer reviewed, have limited numbers of patients, different patient populations or other differences from our patients.


While this study doesn’t necessarily vindicate Trump’s HCQ advocacy, it certainly keeps the debate alive.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: